Metabolic SyndromeNCT07702123
Efficacy of Physical Activity Program in Metabolic-syndrome Females With Behcet Disease
A study testing treadmill walking in people with Metabolic Syndrome and Behcet Disease, run by Cairo University at 1 site in Egypt.
Trial summary
metabolci syndrom is highly prevalent in behcet disorder females. usually physical activity is recommended to solve this problem Read more about this study
- Who is it for?
- Ages 40 to 50 years, women only
- Conditions the study is for
- Metabolic Syndrome, Behcet Disease
- What is being tested?
- treadmill walking
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteEgypt
- Study dates
- 2 Jun 2026to 14 Sep 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 50 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- females with metabolci syndrome
- females with behcet disorder
Who cannot join
- psychatric diseases women
- mental diseased women
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site, 1 recruiting
- Recruiting
Cairo University
Giza, Dokki
ali ismail, lecturer, 02 01005154209, ali.mohamed@pt.cu.edu.eg
About this study
metabolci syndrom is highly prevalent in behcet disorder females. usually physical activity is recommended to solve this problem
Read the detailed description
metabolci syndrom-fenales with behcet disorder (n=40) were assigned to group I or group II. Group I will perform treadmill walk for 40 minutes. group II will act as waitlist. the group will contian 20 females
- Conditions
- Metabolic Syndrome, Behcet Disease
- Being tested
- treadmill walking
- Medical subject headings
- Metabolic Syndrome, Behcet Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
treadmill walkingBehavioural
metabolci syndrom-females with behcet disorder assigned to group I (n=20) will perform treadmill walk for 40 minutes, thrice weekly, for 12 weeks
| Study group | Role | What they receive |
|---|---|---|
| group I | Experimental | metabolci syndrom-fenales with behcet disorderallocated to Group I (n=20) will perform treadmill walk for 40 minutes. Receives: Behavioral: treadmill walking |
| group II | No intervention | metabolci syndrom-females with behcet disorder (n=20) allocated to Group II (n=20) will act as waitlist group. |
What is being measured
The primary outcome is the main question the study is designed to answer.
high density lipoprotin
it is a lipid profile component
Measured: it will be asessed after 12 weeks
Secondary outcomes (14)
triglycrides
it is a lipid profile component
Measured: It will be assessed after 12 weeks
body mass index
it will be assessed on empty stomach
Measured: It will be assessed after 12 weeks
waist circumfrence
it will be assessed with inelsatic tape
Measured: It will be assessed after 12 weeks
fasting blood glucoses
it will be assessed in plasma
Measured: It will be assessed after 12 weeks
systolic blood presssure
it will be assessed at brachial artery
Measured: It will be assessed after 12 weeks
diastolci blood pressure
it will be assessed at brachial artery
Measured: It will be assessed after 12 weeks
subjective vitality scale
A questionaire will assess vitality of subjects
Measured: It will be assessed after 12 weeks
satifaction with life scale
A questionsire will assess satisfaction with life
Measured: It will be assessed after 12 weeks
ptisburg sleep quality index
A questionsire will assess sleep level
Measured: It will be assessed after 12 weeks
fatigue severity scale
A questionsire will assess fatigue level
Measured: It will be assessed after 12 weeks
Behcet disease -related life quality questionaire
A questionsire will assess life quality
Measured: It will be assessed after 12 weeks
ruffier index
it will assess fitness of cardiopulmoanry system
Measured: It will be assessed after 12 weeks
Hamilton anxiety rating scale
A questionsire will assess anxiety
Measured: It will be assessed after 12 weeks
Hamilton depression scale
A questionsire will assess depression
Measured: It will be assessed after 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jul 2026
- Study start2 Jun 2026
- Primary completion14 Sep 2026 (estimated)
- Study completion14 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Metabolic SyndromeStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ali Mohamed Ali ismail, Cairo University
- Investigators
- Ali MA Ismail, lecturer, Principal investigator, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07702123
- Sponsor's protocol ID
- IRB000-14233-86
- Status last verified
- Jul 2026
- First submitted
- 9 Jul 2026
- Last updated
- 14 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Physical Activity Program in Metabolic-syndrome Females With Behcet Disease
- ClinicalTrials.gov ID
- NCT07702123
- Acronym / sponsor ID
- IRB000-14233-86
- Conditions
- Metabolic Syndrome, Behcet Disease
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 2 Jun 2026 (actual)
- Primary completion
- 14 Sep 2026 (estimated)
- Study completion
- 14 Sep 2026 (estimated)
- First posted
- 14 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
metabolci syndrom is highly prevalent in behcet disorder females. usually physical activity is recommended to solve this problem
Detailed description
metabolci syndrom-fenales with behcet disorder (n=40) were assigned to group I or group II. Group I will perform treadmill walk for 40 minutes. group II will act as waitlist. the group will contian 20 females
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| group I | Experimental | Behavioral: treadmill walkingmetabolci syndrom-fenales with behcet disorderallocated to Group I (n=20) will perform treadmill walk for 40 minutes. |
| group II | No intervention | –metabolci syndrom-females with behcet disorder (n=20) allocated to Group II (n=20) will act as waitlist group. |
Who may qualify
- Ages
- 40 to 50 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- females with metabolci syndrome
- females with behcet disorder
Key exclusion criteria (2 listed)
- psychatric diseases women
- mental diseased women
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| treadmill walkingmetabolci syndrom-females with behcet disorder assigned to group I (n=20) will perform treadmill walk for 40 minutes, thrice weekly, for 12 weeks | Behavioural | group I |
Primary outcome
high density lipoprotin
Time frame: it will be asessed after 12 weeks
it is a lipid profile component
14 secondary outcomes
triglycrides
Time frame: It will be assessed after 12 weeks
body mass index
Time frame: It will be assessed after 12 weeks
waist circumfrence
Time frame: It will be assessed after 12 weeks
fasting blood glucoses
Time frame: It will be assessed after 12 weeks
systolic blood presssure
Time frame: It will be assessed after 12 weeks
diastolci blood pressure
Time frame: It will be assessed after 12 weeks
subjective vitality scale
Time frame: It will be assessed after 12 weeks
satifaction with life scale
Time frame: It will be assessed after 12 weeks
ptisburg sleep quality index
Time frame: It will be assessed after 12 weeks
fatigue severity scale
Time frame: It will be assessed after 12 weeks
Behcet disease -related life quality questionaire
Time frame: It will be assessed after 12 weeks
ruffier index
Time frame: It will be assessed after 12 weeks
Hamilton anxiety rating scale
Time frame: It will be assessed after 12 weeks
Hamilton depression scale
Time frame: It will be assessed after 12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jul 2026.
Related trials for Metabolic Syndrome
RecruitingObservational study
Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia
Fanconi Anemia, Inherited Bone Marrow Failure Syndrome
Not yet recruitingPhase 2
Osilodrostat for Glycemic Control in Mild Autonomous Cortisol Secretion (MACS) With Difficult-To-Control Type 2 Diabetes - A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
Mild Autonomous Cortisol Secretion (MACS), Diabetes Mellitus (Type 2)
Active, not recruiting
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis
Not yet recruitingObservational study
Clinical Genetics Branch Eligibility Screening Survey
Melanoma, Li-Fraumeni Syndrome
Not yet recruitingPhase 2
Effects of Meal Macronutrients on Postprandial Lipids
Nephrotic Syndrome, Lipodystrophy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ali MA Ismail, lecturer principal investigator
Cairo University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing treadmill walking in people with Metabolic Syndrome and Behcet Disease, run by Cairo University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ali Ismail, lecturer (+201005154209, ali.mohamed@pt.cu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
high density lipoprotin (time frame: it will be asessed after 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2026.